GW Pharmaceuticals, a bio-pharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its cannabinoid product platform, announced that the United States Food and Drug Administration (FDA) has granted their product, Epidiolex, Fast Track designation in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. FDA’s Fast Track program facilitates the […]